Your Cart is Empty
Free delivery
🇨🇭 "CH" from CHF 100.- 🇨🇭
🇫🇷 "EU" from CHF 200.- Shipping from France 🇫🇷
HortaPharm B.V.
is a cannabis research company headquartered in the Netherlands.
Industry: Horticulture
Founder: David Paul Watson
The head office: Amsterdam, Netherlands
Produits: Cannabis seeds and clones
History
The company was founded by American David Watson, also known as Sam Selezny or "SkunkMan Sam", in the early 1990s, with seeds obtained from Sacred Seeds in California. David, Pate, Michael Taylor (aka Michael Rich) and Robert C. Clarke were the company's original co-founders. From September 1994 to September 1997, HortaPharm had a permit from the Dutch Ministry of Health for scientific research on cannabis; this permit was canceled due to compliance issues. In 1998, HortaPharm B.V. began working with GW Pharmaceuticals to develop cannabis strains for use in the manufacture of pharmaceutical products.
Research
HortaPharm B.V. has used selective breeding and production for cannabis strain research, with a focus on the isolation of tetrahydrocannabinol or cannabidiol. GW Pharmaceuticals holds exclusive rights to all genetics produced by HortaPharm B.V with the aim of producing unique sterile female plants to control supply. Co-founder David Pate gave a lecture at the National Academy of Sciences in Washington, D.C. on February 24, 1998, as part of the Institute of Medicine's study to evaluate the therapeutic value of marijuana and its chemical components.
Patents
In March 2000, HortaPharm B.V. filed a patent for a vaporizer with improved isolation chambers for upward vapor extraction, with the invention attributed to David Pate. GW Pharmecuticals has filed several patents based on its work with HortaPham B.V. and the inventions of David Pate.
GW Pharmaceuticals Limited
is a British pharmaceutical company known for its multiple sclerosis treatment product, nabiximols (brand name, Sativex), which was the first natural derivative of the cannabis plant to gain market approval in any country. Another cannabis product, Epidiolex, was approved for the treatment of epilepsy by the United States Food and Drug Administration in 2018. It is a subsidiary of Jazz Pharmaceuticals.
Industry: pharmaceutical
Founder: Geoffrey Guy
Brian Whittle
The head office: Cambridge, United Kingdom
Key people: Justin Gover (PDG)
Products: Epidiolex (Epidyolex in Europa)
Nabiximols (Sativex)
Company: Jazz Pharmaceuticals
Histoiry
GW Pharmaceuticals was founded in 1998 by Drs Geoffrey Guy and Brian Whittle. That year, they obtained a cultivation license from the UK Home Office and the MHRA, authorizing the company to cultivate, possess and supply cannabis in order to conduct scientific research into medical cannabis. Later in 1998, GW Pharmaceuticals entered into a contract with Hortapharm B.V., a cannabis research and development company based in Amsterdam. In 2001, GW Pharmaceuticals was listed on the Alternative Investment Market, the junior market of the London Stock Exchange. In May 2013, the company became dual listed on NASDAQ and AIM. In 2014, the company entered into an agreement with New York to develop clinical trials using cannabidiol (CBD) to treat children suffering from seizures and other medical complications. In May 2021, Jazz Pharmaceuticals acquired the company.
Products
Sativex
Le nabiximols (commercial name « Sativex ») is a botanical medicine which is an extract of cannabis, administered in the form of an oral spray; it was approved in the United Kingdom in 2010 as a treatment for patients with multiple sclerosis (MS) to relieve neuropathic pain, spasticity, overactive bladder and other symptoms. Nabiximols is made from two unknown cannabis strains and is extracted with ethanol and carbon dioxide. In 2020, GW Pharmaceuticals entered into a partnership with Bayer for the distribution of Sativex in the United Kingdom. Its annual production is estimated at 100 tonnes of medicinal cannabis.
Epidiolex
En 2015, GW Pharmaceutical has initiated phase 3 clinical trials of a cannabidiol oral solution for the treatment of two rare diseases in children: Dravet syndrome and Lennox-Gastaut syndrome. In August 2015, GW received FDA Accelerated Development Program designation from the U.S. Food and Drug Administration for use of the drug candidate to treat newborns with epilepsy. The drug, under the brand name Epidyolex, received approval from the United States Food and Drug Administration in June 2018. It subsequently received European approval from the EMA in September 2019 under the brand name Epidyolex .
1) “Legal conflict surrounding HortaPharm’s authorization for THC: Watson on appeal after rejection”
In September 1994, HortaPharm BV obtained an opium and cannabis license from the Ministry of Health. The Watson Company used tetrahydrocannabinol (THC) for chemical analytical research. THC is a substance extracted from hemp that can be used for medicinal purposes. This authorization was only intended for research and not for the cultivation of marijuana. Additionally, the administration of THC to humans was not permitted. Nowadays, this authorization has expired and a second application has been rejected. In response, Watson unsuccessfully attempted to obtain a stay of execution and is now appealing that decision. Watson was also denied his appeal to the Appeals Council.
An opinion on the matter is currently on the minister's desk, with Watson once again unsuccessfully arguing his point. Watson cannot comment on this situation at this time. He will not provide an official response until next week. He sees the early leak of the notice as a new expression of animosity toward his company. “Apparently the intention is to discredit me and harm my company.” At this time, Watson felt his back was against the wall and had to defend himself on all fronts, including in the context of a parliamentary question, which noted his mention in the computer register of the prosecutor in Santa Cruz, California. He was reportedly arrested more than thirteen years ago for growing hemp.
Watson has hired a lawyer for the case. This week, he filed a request in Santa Cruz in an effort to restore his client's reputation. According to an employee of the lawyer R. Schentz, Watson is entered in the computer register, but that's it. There were no legal proceedings or convictions. “On the day of the arrest, I was not even in Santa Cruz, but in the Netherlands,” Watson commented.
2) Controversy surrounding Sam the Skunkman and the Sacred Seeds raid: conflicting accounts and accusations of genetic ownership
Sam the Skunkman claims he was not present during the Santa Cruz raid. However, according to your source, he was actually present during the famous raid also in Santa Cruz at Sacred Seeds. This incident involved the confiscation of seeds, stored pollen, equipment and plants, which were allegedly thrown into a dumpster by the DEA.
It is said that Sam the Skunkman was a member of the Sacred Seeds collective. He is criticized for apparently appropriating genetics developed by others and profiting from them, such as with Skunk #1, whose aroma he modified by removing the skunk note.
Another figure mentioned is Romulan Joe (formerly Mendocino Joe), accused of similar behavior: claiming genetics that he did not develop and profiting from them.
There appear to be conflicting accounts and disputes about the members and events surrounding the Sacred Seeds collective, as well as accusations of theft and misinformation within the cannabis community.
3) Use of molecular markers to distinguish legal and illegal Cannabis crops
Summary : Cannabis sativa L. (Cannabaceae) is one of the earliest known cultivated plants and plays an important role in the global economy today as a licit and illicit crop. Molecular markers to distinguish between licit and illicit cultivars have forensic utility, but no direct comparison between hemp and marijuana based on amplified fragment length polymorphisms (AFLPs) has been made to date.
Genetic variation was studied in three fiber hemp populations and a potential marijuana crop using AFLP markers. Ten primer pairs generated 1206 bands, 88% of which were polymorphic.
Eighteen bands represented fixed differences between all fiber hemp populations and the marijuana cultivar. These markers have practical use for
4) HortaPharm and GW Pharmaceuticals: A juicy collaboration
"Here's some explanation about 'Sam, the cannabis crusader.
“It looks like cannabis, but it’s really hope,” explains the owner, American entrepreneur David Watson.
In-depth analysis of cannabinoids and development of medical varieties
HortaPharm's sample plants are analyzed in the laboratory with a gas chromatograph and with each new batch, the team focuses on the plant's distinct chemical components or cannabinoids - THC, CBD, CBC, CBG and THCV.
When Dr Guy completes his medical research in Britain, HortaPharm will grow plants to provide the right combination of active ingredients for his treatment.s.
“Once Dr Guy determines what he wants in terms of chemical form, we will also find the right physical characteristics for it by combining desirable traits found in plants around the world – high resin production and disease resistance” . Says Mr. De Meijer.
HortaPharm is only interested in the development of sterile female plants, but this does not only concern the protection of their genetic property rights.
“If a plant is not busy producing seeds, all its energy can be devoted to producing resin,” says de Meijer.
Sitting in front of his computer screen in Amsterdam, Mr Watson can monitor the perimeter fence of Dr Guy's British farm via the Internet.
“The security he has there is incredible,” says Mr Watson, who flew to plant the first seeds two months ago.
In June, Dr Guy's company, G W Pharmaceuticals, was granted the first UK license to grow the plant for medicinal purposes. By arrangement with the Home Office, the doctor can cultivate cannabis plants and study their properties with a view to marketing an inexpensive herb to help patients with the debilitating symptoms of multiple sclerosis, glaucoma, Parkinson's disease, cancer, asthma and AIDS."
GW Pharmaceuticals Patent Protection Strategies for Sativex
There is no doubt that GW plans to enforce its patents on Sativex, a precisely dosed drug.
Guy warns:
“To protect our considerable investment, we have sought to identify and patent certain inventions throughout the cultivation, extraction and manufacturing process. My comments to Mr. Lucas were a friendly and hopefully helpful gesture, as I did not want him to invest a lot of effort into getting a product approved as a prescription drug only to find out that 'he didn't have the freedom to operate from the start. »
Guy's warning was repeated shortly after my arrival in England to interview him, when Mark Rogerson, the man with graying temples and sartorial elegance, GW's public relations manager, met me at Oxford station.
“Once approved and Sativex becomes a medicine under the law, there will have to be a slight change in the legislation so that it can be prescribed,” he said, while driving his Hyundai (his Audi being at the garage).
“The Home Office has already said it will do this, and then patients will be able to take a legal medicine. But if you have multiple sclerosis, it would still be illegal to grow cannabis in the garden to treat your symptoms. Our medicine will be legal, but anything else will not be.
Exclusive agreement between GW Pharmaceuticals and HortaPharm
At the International Cannabinoid Research Society (ICRS) conference in Montpellier, Dr. Geoffrey W. Guy, president of GW Pharmaceuticals, said HortaPharm will provide GW with exclusive access to its entire range of cannabis strains for drug development.
The worldwide rights acquired by GW for an undisclosed sum cover varieties grown to date, with a few exceptions, as well as any varieties to be developed in the future. Plant records from the Dutch breeding program will be the property of GW.
GW Pharmaceuticals: Inside Europe's most advanced culture rooms
In a secret location in the south-east of England, GW Pharmaceuticals has built what may well be the most high-tech cannabis palace on the planet. Surrounded by electrified barbed wire, video cameras and motion detectors, the greenhouse extends over more than 4000m2 of land.
At any given time, more than 15,000 marijuana plants grow under its 13-foot-high ceiling, lit by rows of lamps.
Inside, it's an ocean of green, made up of some of the most potent cannabis strains in the world at the moment: Hindu Kush, White Widow, Skunk, Northern Lights. Outside of the Netherlands, GW is the only commercial organization in Europe authorized to cultivate cannabis on this scale.
Impact on cannabis biodiversity: The controversy surrounding Monsanto's Terminator technology
“Monsanto’s Terminator technology is being applied to cannabis by (David Watson) at Hortapharm in the Netherlands. »
Terminator seeds are genetically modified to produce a plant that will not produce viable seeds, meaning growers would be forced to return to Monsanto every year to purchase more seed stock for replanting. Governments and the public became wary of this concept when it was discovered that the terminator seed could possibly cross the species barrier, thereby spreading infertility within the plant kingdom like a virus or disease.
Seed Conservation: A Sacred Concept Across World Cultures and Religions
As we can learn from the Mayans in the previous article, the concept of saving seeds is sacred in both the spiritual and physical way of life. The same goes for cultural and religious practices around the world: whether you are Christian, Buddhist, Hindu, Muslim, Jewish or just an old human being, the concept of seed saving is as old as human society itself .
Control, regulation and potential implications
Only companies like Monsanto, GW Pharma, Bayer and HortaPharm are allowed to exercise their passion, they will own the genetic copyrights to every cannabis strain on the planet, if they don't already....
GW Pharma and HortaPharm have declared their intention to create cannabis strains similar to Monsanto's terminator seed technology. Their strains appear to be artificially manipulated to produce "unique sterile females", which prevents reproduction of the
harvestable seeds. These are the kind of strains that are waiting to be controlled, regulated, licensed and taxed after the eventual passage of Prop. 19 in California and numerous similar initiatives in the United States funded directly by Monsanto shareholders themselves.
5) Here are some quotes about Sam
Quote 1: « Monsanto Cannabis Seeds Are Almost Definitely Genetically Modified “GMO”.
Genetically modified plants can be patented, and it is in Monsanto's best interest to hold a patent on all the seeds it sells. Seed patents ensure that companies like Monsanto can continue to profit from seeds year after year, because farmers are legally required to purchase patented seeds from the patent holder rather than simply storing them at home. seeds from last year's harvest.
Quote 2: Evidence of an attempted Canadian monopoly on medical marijuana began in 2000, with a leak of an unpublished document titled "Draft Statement of Work for the Development of a Comprehensive Cultivation and Manufacturing Operation." marijuana in Canada".
The plan called for a monopoly on seeds, "a licit source only, and the eventual phasing out of all consumable products except pharmaceuticals. According to the anonymous source who leaked the document, the first version of the plan also provided that cannabis strains be patented 'as if they had been genetically modified' It appears that GW Pharmaceutical and Bayer have now done this with the 'Grace' cannabis strain.
Quote 3: Cannabis monopolies are nothing new.
It can be stated that the prohibition of the sacred anointing oil of Moses*** “found in Exodus 30:32”
a ban on people other than priests and kings – was a kind of cannabis monopoly. When botanical medicine became popular again in the 1400s, women healers were the first to be labeled "unschooled" and then "witches" to prevent them from competing with the new male pharmacists. The same thing happened in the mid-1800s, except this time, instead of “witches,” these botanical healers were called “charlatans.”
*** Anointing oil has deep meaning in Judeo-Christian traditions. According to the book of Exodus (30:22-25), God commanded Moses to prepare a holy oil from myrrh, cassia, calamus and olive. This oil was used to anoint the tent of meeting, sacred utensils and priests. It was considered a sacred substance, reserved exclusively for liturgical use..
Anointing oil symbolizes sanctification and consecration. It is a link between the revered past and our current spiritual quest. This age-old tradition continues to inspire believers, recalling the divine election and the holiness of religious authorities.
Quote 4: A source within the Ministry of Health, who wishes to remain anonymous, provided documents and information to Cannabis Culture, outlining how Canadian pot will be grown for upcoming medical trials.
The documents call for 200 kg of pot to be grown in the first year, and double that amount in the second and so on until the fifth year. The thirty-five page guidance document, bearing the cumbersome title “Draft Statement of Work for the Development of a Comprehensive Marijuana Cultivation and Manufacturing Operation in Canada,” is still open to revisions. It includes proposals for how marijuana should be grown, processed and manufactured. These guidelines include the possibility of granting a well-known pharmaceutical company exclusive rights to sell seeds to the burgeoning “medpot” industry.
“Cannabis ready for the Round-Up, here we come!” This is Sam's contribution to our community, in addition to ruining the Skunk seeds with the Terminator project owned by GW pharm ».
How much royalties could be due once all the common "basic" strains are patented like Romulan, White Widow, Haze, Skunk #1, Northern Lights etc? Patents on cannabis varieties will only be a good thing for old people. Especially since Bayer has now licensed GW Pharma to produce Sativex, Monsanto is in the mix and of course HortaPharm has divested and licensed its genetic base to GW (and of course you need to research "Kennex » and “Novartis” on this subject). All courtesy of weed world betrayal and backstabbing pirate extraordinaire David Watson pissing the snitch he was/is with the bitch known as Robert Connell Clarke.
BigPharma's power over MMJ is already there, people who "think" they are currently "players" within the industry, like Richard Lee, Ken Estes (both of whom have the ethics of a shit rat), Harborside***, etc. are in the process of moving for the arrival of the BIG players.
*** Harborside is a well-known company in the cannabis industry. Here is some information about it :
Founded in 2006, it is one of the first companies to operate legally in the state of California.
Operating multiple medical and recreational cannabis dispensaries in California.
It offers a variety of products including cannabis flowers, concentrates, edibles and CBD products.
The company played a key role in the legalization and normalization of cannabis in the United States.
His success and commitment to quality and compliance influenced other companies and contributed to the growth of the industry.
However, it is important to note that Harborside's influence is relative to the region of California and the changing cannabis laws in that state.
In summary, Harborside is a big company in the cannabis market, and its impact has been significant, particularly in the state of California..
And they want to patent the genetics. Especially around the new push of high CBD strains. And of course, the idiot pirates also moved into this area, as if it was something new since pre-prohibition "hemp" varieties were very high in CBD and CBN while having low THC content.
But because these varieties still exist and are grown in much of the world for industrial hemp, seed companies are trying to keep them from the medical market, and only the global "medical" seed market..
A billion dollar a year business. And once again, HortiPharm is the “ONLY” DEA licensed seed and gene production company in the world. Provides genetics to the laboratories and facilities of the University of Mississippi, and David Watson did not exist until he arrived in Amsterdam in 1985, somehow transporting between 2 and 10 Kg of seeds. .. Strange isn't it that it came out after the Sacred Seeds bust and the rest of the people are locked up, and when you're on the run from the DEA how do you get to Amsterdam with pretty much ALL the genetics NorCal in tow?...Traitor….
Quote 5: Joe is also a snitch thief who admits in his book to helping the DEA, but the fact remains that there is ample evidence that Sam is a DEA snitch and is actively working to both control and destroy the cannabis gene with Terminator technology.
Meanwhile, on October 18, 2006, a few months after Dr. Barthwell left to work for GW, Charlotte Figi was born in Colorado. “At 3 months, she had her first seizure. Due to her Dravet syndrome, by the age of five she used a wheelchair, had up to 300 grand mal seizures a week and struggled to speak.
In 2012, Figi's mother researched "CBD marijuana oil" for her daughter's treatment. Figi began taking oil from the “Hippie’s Disappointment” marijuana plant, which contained low THC and was later renamed Charlotte’s Web. Using Charlotte’s Web, Figi saw an immediate reduction in her seizures, going from 300 per week to two or three per month.
In 2014, GW patented Epidiolex. This was two years after Charlotte Figi's mother discovered the ironically named CBD. So should the Figi's have been arrested for giving their child a drug that wouldn't be approved by the FDA for another four years?
As prohibitionists like to say: “Think of the children!” How many children and their families suffered because Dr. Barthwell's former employer opposed medical marijuana?
Meanwhile, in the UK, does GW still support marijuana prohibition? GW has a market value of more than $2 billion, or about 20 times its revenue. On the other hand, they have huge greenhouses filled with some of the best genetics in the world that they sourced from American marijuana refugees. I wonder what Dr. Barthwell would say about that.
7) GW Pharmaceuticals Announces Grant of New U.S. Patent
GW's intellectual property portfolio includes several patent families with issued and/or pending claims relating to plants, plant extracts, extraction technology, pharmaceutical formulations, drug delivery and therapeutic uses of cannabinoids, as well as plant variety rights, know-how and trade secrets. . The main link that binds us is Sativex... Sativex is made by GW but old David Watson is everywhere.
The Sativex feasibility study in China :HERE
HortaPharm quickly crossed paths with Dr. Geoffrey Guy, who in 1998 received a license from the British government to grow pot for medical purposes for his company: GW Pharmaceuticals. Guy was looking for a legal source of plant materials containing various compositions of cannabinoids. He wanted to hybridize different plant varieties so that he could test the effects of various cannabinoid combinations on various diseases.
8) Coroner rules Sativex responsible for patient's death
Death following a study on Sativex:HERE
An experimental drug made from the marijuana plant, known as Sativex, is responsible for the death of Rene Anderson, a diabetic pensioner, a UK coroner has ruled. The medication was prescribed to Ms. Anderson to relieve numbness and pain in her limbs caused by diabetes. The medication reportedly caused behavioral disturbances and the patient was subsequently taken to hospital in an intoxicated and confused state. Here his condition continued to deteriorate, leading to his death from kidney failure five months later at the Northern General Hospital. The coroner admitted that the reason for Ms. Anderson's continued deterioration, even after she stopped taking the medication, was unknown. Sativex is manufactured by GW Pharmaceuticals to relieve severe pain.
Company sources insist that more than 2,000 people received the drug during its development and there were no deaths. The project is funded by Diabetes UK and is licensed in Canada. Ms Anderson's family insists further trials of the drug be banned, saying patient was used as guinea pig for dangerous drug.
Cannabis-based medicine launched in UK:
GW creates Sativex by processing cannabis plants it grows in secret facilities at an undisclosed location in the UK. Sativex cost £100m to develop and was based on selective breeding of two different types of cannabis plant that were acquired in 1998 from Dutch cannabis researchersHorta Pharm, which has a non-disclosed share in the success of Sativex.
Let's keep following the money...$$$
Sativex is now a Bayer product. Bayer buys marketing rights to GWP's cannabis extract
Bayer Buys Rights to Market GWP’s Cannabis Extract -> HERE
9) Israel can now patent our seeds:
In America, Charlotte's Web is the most well-known no-effect medicinal cannabis strain, thanks to a CNN special. In Israel, where medical marijuana is legally prescribed and dispensed in pharmacies, their non-psychoactive variety is called Avidekel. Both strains have been bred to be very high in CBD, one of the non-psychoactive components of marijuana. Both are very low in THC, which causes the classic effect.
KanaboSeed wants to go even further with patented varieties for different diseases.
One of eight licensed Israeli growers, Seach Ltd., teamed up with an Israeli software developer in August to create designer cannabis strains with specific characteristics, David Shamah reports for The Times of Israel. The joint venture KanaboSeed has just filed an application for its first two “registrations” of Israeli patents, for new varieties of marijuana. Hearings are held and public comments are requested before applications can be approved.
KanaboSeed's head of research and development credits BreedIT, the software developer, with providing valuable input into the process. “Besides saving time,” said Shay Avraham Sarid. “We are also developing new varieties more cost-effectively. »
Sarid said they were able to streamline the breeding process to create more and more specific varieties.
BreedIT CEO Dr. Oded Sagee believes his company's technology is vital to the medical marijuana industry. He doesn't think current marijuana strains provide the greatest possible medical benefit and believes he can do better.
“We believe that with our knowledge and experience, we will be able to develop new breeds that will be more effective,” Sagee said in a recent interview.
In Israel you can patent a variety of marijuana. In America you can't even look for one
10) The hunt for genetics and unregistered companies
Leaves of Grass Coyle calls its DNA typing system NMI01, named after the National Marijuana Initiative, led by Tommy LaNier in San Diego.
“He acts as our liaison to other drug task forces and pharmaceutical companies and has provided us with samples to test,” Coyle said.
LaNier told Forensic that the DNA database was created to help law enforcement connect wholesale and retail locations or those in the distribution industry of marijuana production. The database is there to support all law enforcement and those assigned to special anti-drug forces.
“We would use it in seed or cloning operations,” LaNier said.
LaNier has previously used the DNA database to prosecute marijuana cases in the San Diego area. In one case, a group of individuals owned several indoor grow houses.
“The seized marijuana was tested and we were able to determine that the homes were all using a cloning operation, thus establishing connections to the homes and growers,” LaNier said. The defendants all plead in this case.
LaNier said using the database also helps authorities determine seed stock used around the world.
“It also gives us a better idea of plant lineage with different growers and those selling seed stock on the Internet,” he said.
The samples are sent to Coyle on plant collection cards, similar to how human DNA is collected for CODIS processing for human identification.
Collection cards allow law enforcement to easily collect a genetic fingerprint of marijuana. The cards work like this: Officers take a marijuana leaf or bud sample from seized evidence, rub the sample on the card, then send the card to the lab. In the laboratory, a small part of the card is cut out, inserted into the DNA sequencer and compared to other DNA samples in the database. Coyle said processing and examination takes 5-8 days.
“Samples are obtained from law enforcement through the High Intensity Drug Trafficking Areas program, a federally funded program involved in marijuana eradication and tracking efforts,” Coyle said. HIDTA, part of the Office of National Drug Control Policy, was established in 1989 by the Anti-Drug Act of 1988; its stated purpose is to establish policies, priorities and goals to eradicate the consumption, manufacture and trafficking of illicit drugs, drug-related crime and violence, and drug-related health consequences in the States -United.
And after? Coyle said that over the next few months, the cannabis DNA database will be analyzed for statistical correlations using various methods and software to establish what the optimal forensic match statistics might be for the system.
“Like other genetic typing systems, additional genetic markers can be added to increase the individualizing power of the method,” she said.
Coyle said inbred lines of animals, such as cats and dogs, use DNA-based markers of more than 20 to 30 short tandem repeat loci.
“The NMI01 system is somewhat unique in that the cannabis genetic barcode appears to be quite discriminating even with 1-2 loci and is quite species specific,” she said. Coyle said it's likely that this is due to the unique cannabinoid chemistry found in marijuana.
Current work on the database involves calculations of match statistics, which concern mathematical modeling for comparing match statistics within a closed population versus using this technique as an open research tool.
“Having known reference genetic populations with which to compare some of the street, dispensary and public land seizures has been very informative,” Coyle said.
The development of an efficient format for archiving plant evidence for DNA and chemistry based identification from collection cards is new to law enforcement and can be easily expanded to other plant materials to preserve DNA from crime scene samples.
References
Monitoring the Future survey, University of Michigan, National Institute on Drug Abuse
11) Gw was an underground Monsanto company
Bayer has partnered with GW Pharmaceuticals on cannabis since at least 2013. Bayer recently purchased Monsanto. Chimera has also worked with the GW Pharmaceuticals team and is the lead breeder for a company that holds the first USPTO patent on a cannabis plant Veritas Pharma Inc.
Founder : Ryan Lee
Management of chimera genetic resources
Ryan Lee is a cannabis breeder, author and researcher specializing in cannabis genetics – with a unique focus on developing custom cultivars of desired cannabinoid and terpene composition.
Recognized throughout the industry for his broad understanding of cannabis genetics and metabolites, Ryan is an expert in manipulating the plant's biosynthetic pathways. Through intensive laboratory research into the chemotypic clustering of cannabis strains and the mechanisms of inheritance of metabolites produced by the plant, Ryan has become a recognized international speaker in the fields of cannabis genetics and breeding.
Founder of European company Chimera Genetic Resource Management and Canadian Chemovar Consulting, Ryan has worked with the most advanced cannabis groups to develop tissue culture protocols for standardized seedling production, as well as to design and implement programs breeding focused on the development of unique medicinal and adult plants. use varieties. Ryan was the principal breeder of the program to develop the first cannabis cultivars to be granted patent protection by the USPTO, is a registered founding member of the Federal Marijuana Party, and now operates a consulting practice based on the development and improving the genetic potential of cannabis.
Long planned, watch here. :HERE
12) Bright Green Group : is a company that positions itself in the field of cannabis. Here is some information about them
- Pioneer of the “Drugs Made in America” movement»: Bright Green is a licensed manufacturer of herbal medicines and active pharmaceutical ingredients (APIs) in the United States. They have received federal authorization to produce Schedule I and II herbal medicines, including psilocybin, mescaline, peyote, ibogaine, cannabis, opium and its derivatives. Their goal is to establish a reliable supply chain for domestic APIs.
- EB-5 Offering : In partnership with Asia Capital Pioneers Group (ACPG), Bright Green launched an unprecedented EB-5 program to raise $500 million to expand their state-of-the-art greenhouse facilities for the production of herbal medicines.
- Research and development : Bright Green focuses on high-tech sustainable agriculture, manufacturing and research to ensure the effectiveness, purity and quality of their products.
- Bright Green Corp (BGC) : This company aims to provide safe and reliable products to patients requiring medicinal cannabis. Their mission is to improve people's lives through natural plant-based solutions.
- Bright Green Breaks Ground On $300 Million Cannabis Research Complex : This company provides legal access to federally authorized researchers to high-quality cannabis products.
- In summary: Bright Green Group is involved in the production of herbal medicines, with a focus on quality, compliance and research. Feel free to explore their websites further to get more information
Canadian John Stockwell is the force behind Bright Green Group and also has Sam the Skunk and Robert Clarke in his pocket and everything mentioned is applied today...
We're all fucked up….
